AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information <u>(including phone and fax #s)</u> on this form is correct. <u>If the information provided is not</u> complete, correct, or legible, the authorization process can be delayed.

Drug Requested: icosapent ethyl (Vascepa[®])

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
Member AvMed #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	
DEA OR NPI #:	
DRUG INFORMATION: Authorization may be delayed if incomplete.	
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

DIAGNOSIS - Hypertriglyceridemia (severe). ALL of the following criteria must be met:

□ Member's current triglyceride level is \geq 500 mg/dL (submit labs documenting current level)

AND

□ Member is on an appropriate lipid-lowering diet and exercise regimen

AND

- Member has a history of failure or intolerance (at least 90 days) to <u>TWO</u> of the following medications (Check all that apply; submit documentation of intolerance and/or contraindication; pharmacy claims will be reviewed)
 - □ Fibrate (e.g., fenofibrate, gemfibrozil)
 - □ Statin (e.g., atorvastatin, rosuvastatin)
 - □ Omega-3-acid ethyl esters (generic Lovaza)

(Continued on next page)

- DIAGNOSIS Cardiovascular Event Risk Reduction. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.
 - □ Member's current triglycerides are between 150 and 499 mg/dL (submit labs documenting current level)

AND

 Use is adjunctive to maximally-tolerated statin therapy unless contraindicated per FDA label or intolerance (submit documentation of intolerance or contraindication; pharmacy claims will be reviewed)

<u>AND</u> (Select **ONE** of the following):

- □ Member is \geq 45 years old with established cardiovascular disease defined by <u>ONE</u> the following: (submit chart notes and/or lab documentation)
 - Documented coronary artery disease (multi-vessel CAD, prior MI, or hospitalization for high risk non-ST segment elevation acute coronary syndrome (NSTE-ACS)
 - Documented carotid artery disease (prior ischemic stroke, arterial stenosis, history of carotid revascularization)
 - □ Documented peripheral artery disease (Ankle-brachial index (ABI) < 0.9 with symptoms of intermittent claudication, history of aorto-iliac or peripheral arterial intervention)

<u>OR</u>

- □ Member is > 50 years old with diabetes mellitus (Type I or Type II) with <u>**TWO**</u> of the following additional risk factors for CVD. Check all that apply; select at least <u>**TWO**</u> additional risk factors below: (submit chart notes and/or lab documentation)
 - $\Box \quad Men > 55 \text{ or women} > 65 \text{ years of age}$
 - □ Cigarette smoker (or recently quit)
 - **u** Hypertension or on antihypertensive medication
 - \Box Low HDL-C (e.g., HDL-C < 40 mg/dL or < 50 mg/d L for women
 - **\Box** Renal dysfunction: (CrCL > 30 and < 60 mL/min)
 - □ Retinopathy
 - Presence of albuminuria
 - □ Elevated biomarkers associated with ASCVD (e.g., hs-CRP > 3.00mg/L, ABI < 0.9 without symptoms)

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required. **Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.** *<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>*

REVISED/UPDATED: 7/22/2010; 9/13/2011; 4/9/2014; 11/2/2014; 5/22/2015; 12/28/2015:1/21/2016; 3/30/2016; 4/26/2016; 12/19/2016; 8/14/2017; (Reformatted) 6/19/2019; 6/11/2020; 8/22/2022; 10/27/2023;